ArticleLangenbeck's archives of surgery2026
Indocyanine green fluorescence during total thyroidectomy: utility for predicting hypoparathyroidism and safety assessment.
Article in Langenbeck's archives of surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeParathyroid fluorescence with indocyanine green (ICG) might prevent and predict postoperative hypoparathyroidism (hypoPT) after total thyroidectomy (TT). We aimed to evaluate parathyroid gland vascularization with ICG during TT. Further, we aimed to evaluate safety of ICG fluorescence and to correlate changes in PTH with postoperative hypoPT after TT.
methodsFrom May 2021 to June 2023, consecutive patients underwent TT and parathyroid fluorescence with ICG. Each visible parathyroid gland was scored 0, 1 or 2 depending on fluorescence intensity. Patients with at least one gland score of 2 were compared to those without. We measured PTH before and after TT, changes in calcium, creatinine and alanine transaminase (ALAT), postoperative alfacalcidol requirements, and adverse events of ICG use.
resultsA total of 124 patients were included. Patients with at least one gland scored 2 (n = 108) had a reduced need for alfacalcidol at discharge compared with those without (8% vs. 38%, p = 0.004), although hypoPT was not fully excluded. Six patients required alfacalcidol after 12 months and were classified as having permanent hypoPT; all had an intraoperative PTH decrease > 83%. Creatinine levels were higher in patients with permanent hypoPT compared to others (p = 0.01). No increases in ALAT or ICG-related adverse events were observed.
conclusionsICG-based parathyroid fluorescence during TT was well tolerated in this cohort and predicted immediate postoperative hypoPT. However, a fluorescence score of 2 did not exclude hypoPT development. The grading system is limited by subjectivity. No permanent hypoPT occurred in patients with a PTH decrease ≤ 83% after TT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.